Microbot Medical Inc. (NASDAQ: MBOT) has received several new patent approvals across the United States, Japan, China, and Canada, bringing its total to 44 issued patents and 49 pending patent applications globally, according to a company statement.

The patents cover technology related to the company's LIBERTY Endovascular Robotic System, a single-use robotic device cleared by the U.S. Food and Drug Administration for peripheral endovascular procedures. The company's patent portfolio spans North America, Europe, Israel, and Asia.

"Our R&D and Business Development teams' ongoing collaboration is resulting in a robust and diverse intellectual property portfolio, which we expect to expand significantly over the coming months," said Dr. Sarit Garten, Director of Intellectual Property. "These developments align with our strategy for market entry into the EU and other jurisdictions."

Microbot Medical is pursuing a CE Mark as it seeks to expand the LIBERTY System into European markets. The company is headquartered in Hingham, Massachusetts.